New Insomnia Drug Class Shows Superior Safety Over Benzodiazepines

How Do Orexin Antagonists Differ from Traditional Sleep Medications?

Traditional insomnia medications — benzodiazepines (temazepam, triazolam) and Z-drugs (zolpidem, eszopiclone) — work by enhancing gamma-aminobutyric acid (GABA) activity, broadly suppressing neuronal excitability throughout the brain. While effective at inducing sedation, this mechanism disrupts normal sleep architecture by reducing slow-wave sleep (deep sleep) and REM sleep, produces significant next-day residual effects (cognitive impairment, psychomotor slowing, driving impairment), and carries substantial risks of tolerance, physical dependence, and withdrawal syndromes. In older adults, GABA-ergic sleep medications have been associated with a significantly increased risk of fall-related hip fractures, with studies suggesting an approximately two-fold or greater increase in fracture risk.

Dual orexin receptor antagonists represent a fundamentally different pharmacological approach. The orexin (hypocretin) system is a neuropeptide signaling network originating in the lateral hypothalamus that serves as the brain's primary wakefulness-promoting system. Orexin neurons are active during wakefulness and inactive during sleep. DORAs selectively block both orexin receptors (OX1R and OX2R), reducing the wakefulness drive without broadly suppressing brain function. This targeted mechanism preserves normal sleep architecture — including slow-wave and REM sleep — and produces minimal next-day impairment because the drug's effect mirrors the natural reduction in orexin signaling that occurs during normal sleep initiation.

Currently approved DORAs include suvorexant (Belsomra, 10–20 mg, Merck), lemborexant (Dayvigo, 5–10 mg, Eisai), and daridorexant (Quviviq, 25–50 mg, Idorsia). Suvorexant was the first DORA approved by the FDA in 2014, followed by lemborexant in 2019 and daridorexant in 2022. All three have demonstrated efficacy for both sleep onset and sleep maintenance insomnia with minimal next-day residual effects in clinical trials.

What Does the Clinical Evidence Show?

Systematic reviews and meta-analyses of randomized controlled trials have established that DORAs are effective for treating insomnia. A meta-analysis by Kishi et al. found that suvorexant significantly improved subjective total sleep time and sleep onset latency compared to placebo. Across trials, DORAs typically reduce sleep onset latency by approximately 15–30 minutes and increase total sleep time by approximately 20–40 minutes — improvements broadly comparable to those seen with benzodiazepines and Z-drugs.

The safety advantages of DORAs over GABA-ergic agents have been consistently demonstrated. Clinical trials show substantially lower rates of next-day cognitive impairment, as measured by driving simulation and psychomotor testing. Fall risk is markedly reduced, which is especially important for older adults — a population in which benzodiazepine-associated falls are a major cause of hip fractures and related mortality. Rebound insomnia upon discontinuation is uncommon with DORAs, in contrast to the well-documented withdrawal and rebound effects seen with benzodiazepines, where physical dependence can develop within weeks of regular use. Studies of suvorexant have shown no evidence of withdrawal symptoms or rebound insomnia after abrupt discontinuation even after 12 months of use.

Based on the accumulating evidence, leading sleep medicine experts and organizations including the American Academy of Sleep Medicine have recommended that DORAs be considered as a pharmacotherapy option for chronic insomnia. Cognitive behavioral therapy for insomnia (CBT-I) remains the recommended first-line treatment overall, with pharmacotherapy reserved for when CBT-I is insufficient or unavailable. Among pharmacological options, DORAs offer particular advantages for older adults (≥65), patients with fall risk, those with cognitive concerns, patients with substance use history, and anyone requiring longer-term treatment.